Sertraline treatment influences [18F]FE-PE2I PET imaging for Parkinsonism

Article Neuroimaging

Longitudinal DAT changes measured with [18F]FE-PE2I PET in patients with Parkinson?s disease; a validation study

V. S. Kerstens et al.

Summary: This study validates the efficacy of [18F]FE-PE2I PET as a measurement tool for longitudinal DAT changes in patients with Parkinson's disease. The results show a significant decline in DAT availability measured by [18F]FE-PE2I PET in early-stage Parkinson's disease patients, with larger effect sizes compared to previous SPECT and PET studies. This suggests that [18F]FE-PE2I can be used as a progression marker in clinical trials.

NEUROIMAGE-CLINICAL (2023)

Add to Collection

Article Clinical Neurology

Longitudinal Positron Emission Tomography Imaging of Presynaptic Terminals in Early Parkinson's Disease

Aline Delva et al.

Summary: This study used PET imaging to longitudinally assess presynaptic terminal loss in early Parkinson's disease (PD). The results showed that F-18-FE-PE2I PET was able to detect a significant decline over 2 years in early PD, while C-11-UCB-J PET did not show any changes. However, the changes in F-18-FE-PE2I binding did not correlate with clinical motor progression.

MOVEMENT DISORDERS (2022)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

[18F]FE-PE2I PET is a feasible alternative to [123I]FP-CIT SPECT for dopamine transporter imaging in clinically uncertain parkinsonism

Lisbeth Marner et al.

Summary: This study compared the diagnostic performance of [F-18]FE-PE2I PET/CT and [I-123]FP-CIT SPECT, and found a high correspondence between the two imaging methods. [F-18]FE-PE2I PET/CT was shown to be a feasible PET tracer for clinical use.

EJNMMI RESEARCH (2022)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging